Castle Biosciences completes Cernostics acquistion

By staff writers

December 6, 2021 -- Castle Biosciences has completed its purchase of Cernostics for $30 million. The company will pay up to $50 million more if Cernostics fulfills particular milestones in 2022.

The acquisition expands Castle's offerings to include Cernostics' TissueCypher Barrett's Esophagus Assay, a test that predicts future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, it said.

Castle Biosciences moves ahead with skin cancer test
Castle Biosciences is moving forward with the development of a prognostic gene expression profiling test for cutaneous squamous cell carcinoma. Researchers...

Copyright © 2021

Last Updated ls 12/6/2021 3:22:14 PM